GH1 and pituitary gland adenoma: Among patients with a previous intracranial tumor and evaluable baseline data, no difference in growth or recurrence rates of pituitary adenoma, craniopharyngioma, or other intracranial tumors was observed between GH-treated and untreated patients (Table 6).